Business Context and Reporting Period
This Form 8-K, dated July 31, 2013, reports that PharmAthene, Inc. (the registrant) entered into a definitive Merger Agreement with Theraclone Sciences, Inc. The filing details a proposed stock-for-stock merger of equals, where Theraclone will become a wholly-owned subsidiary of PharmAthene. The transaction is structured so that pre-merger securityholders of both companies will each own approximately 50% of the combined entity's fully-diluted equity.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins for the reporting period, as this is a transactional filing rather than a periodic financial report. Key financial terms of the transaction include:
- Exchange Ratio: Based on the quotient of PharmAthene's Fully Diluted Equity divided by Theraclone's Fully Diluted Equity.
- Escrow Shares: 5% of the merger consideration issuable to Theraclone stockholders will be held in escrow for nine months to secure indemnification obligations.
- Break-up Fees: PharmAthene is obligated to pay Theraclone a fee of $3,500,000 if PharmAthene terminates for a superior proposal. A fee of $4,500,000 is payable if PharmAthene terminates due to a "Transaction Event" (related to the SIGA litigation outcome) or changes its recommendation. An additional $3,500,000 fee applies if the deal fails due to the Outside Termination Date and a takeover occurs within nine months.
- Expense Reimbursement: PharmAthene may be obligated to reimburse Theraclone for expenses up to $1,000,000 in certain termination scenarios.
- Capital Condition: A closing condition requires that all $8,000,000 of capital committed to Theraclone under its Series B-1 Preferred Stock agreement be delivered.
Material Changes and Governance
The filing outlines significant changes to corporate governance and executive compensation contingent on the merger's completion:
- Board Composition: The post-merger board will consist of nine members: five designated by PharmAthene and four by Theraclone. A ninth director is to be designated by Theraclone.
- Executive Leadership: Clifford J. Stocks (Theraclone CEO) is expected to become CEO of the combined company, and Russ Hawkinson (Theraclone CFO) is expected to become CFO.
- Severance and Employment: PharmAthene's existing executive severance plan will be terminated upon merger completion. Employment agreements for executives Eric Richman and Linda Chang will be amended to provide severance benefits comparable to a change of control if terminated within 12 months of the merger, along with extended stock option exercise periods. Other executives will see their severance duration extended from six to twelve months.
- Voting Agreements: Stockholders owning approximately 7.5% of PharmAthene and 75% of Theraclone have entered into voting agreements to support the merger.
Outlook, Risks, and Contingencies
Management commentary and risk factors highlight several critical contingencies and uncertainties:
- Closing Conditions: The merger is subject to shareholder approval from both companies, SEC effectiveness of a Form S-4 registration statement, NYSE MKT listing approval, and the delivery of $8 million in committed capital to Theraclone.
- SIGA Litigation Risk: A "Transaction Event" is defined by a substantive decision in PharmAthene's civil case against SIGA Technologies, Inc. regarding the drug Arestvyr. If the court decision leads the board to conclude the merger is no longer a "merger of equals," PharmAthene may terminate and pay a $4.5 million fee. There is significant uncertainty regarding the financial remedy PharmAthene may receive from SIGA.
- Product Development Risks: The combined company faces risks regarding the safety, efficacy, and regulatory approval of product candidates including Arestvyr, SparVax, TCN-202, and TCN-032. No assurance exists that these candidates will be approved or generate revenue.
- Financing Needs: The combined company may require additional financing, and there is a risk of delays or reductions in U.S. government funding for development programs.
- Outside Termination Date: The deal must be completed by January 31, 2014, unless extended due to delays in the S-4 effectiveness.
Investor Verification Checklist
- Verify the final Exchange Ratio once the Fully Diluted Equity calculations are finalized and disclosed in the Form S-4.
- Monitor the status of the SIGA Technologies litigation and the Delaware Court of Chancery's ruling on the remedy, as this directly impacts the "merger of equals" status and potential break-up fees.
- Confirm the delivery of the $8,000,000 capital commitment to Theraclone as a condition precedent to closing.
- Review the joint proxy statement/prospectus (Form S-4) for detailed financial data on both entities and specific terms of the voting agreements.
- Assess the timeline for the Form S-4 effectiveness, noting the October 4, 2013 deadline for potential extension of the Outside Termination Date.